Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Zenotech Laboratories Ltd

ZENOTECH

Zenotech Laboratories Ltd

ZENOTECH
Health CareBiotechnology
SmallcapWith a market cap of ₹552 cr, stock is ranked 1,780
High RiskStock is 3.96x as volatile as Nifty
90.460.00% (+0.00)
90.460.00% (+0.00)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareBiotechnology
SmallcapWith a market cap of ₹552 cr, stock is ranked 1,780
High RiskStock is 3.96x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
SmallcapWith a market cap of ₹552 cr, stock is ranked 1,780
High RiskStock is 3.96x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
67.826.10—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.066.530.48%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves therapy areas, such as oncology and anesthesiology.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 18.72%, vs industry avg of 20.22%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.27% to 0.25%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2.104.1613.5117.7433.5622.8637.2043.5041.8342.63
Raw Materialssubtract2.001.520.810.710.500.030.000.060.0024.51
Power & Fuel Costsubtract0.981.944.243.683.293.123.253.792.69
Employee Costsubtract2.253.025.074.985.766.497.107.889.46
Selling & Administrative Expensessubtract3.432.933.572.211.751.621.912.002.33
Operating & Other expensessubtract1.073.245.324.975.744.806.847.999.13
Depreciation/Amortizationsubtract3.963.873.904.204.856.466.977.177.097.01
Interest & Other Itemssubtract7.557.502.450.120.891.551.220.110.00—
Taxes & Other Itemssubtract0.000.000.000.000.000.00-12.272.922.842.97
EPS-5.28-5.47-2.44-0.511.77-0.203.631.901.361.33
DPS0.000.000.000.000.000.000.000.00—0.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Zenotech Laboratories Ltd66.606.10—
Biocon Ltd42.331.710.14%
Panacea Biotec Ltd572.076.04—
Hester Biosciences Ltd106.826.660.25%

Price Comparison

Compare ZENOTECH with any stock or ETF
Compare ZENOTECH with any stock or ETF
ZENOTECH
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding68.84%0.00%0.01%0.00%31.15%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ZENOTECH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Zenotech Laboratories schedules AGM

Zenotech Laboratories announced that the 35th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live

Zenotech Laboratories standalone net profit declines 10.42% in the June 2024 quarter

1 month agoBusiness Standard
Earnings
Zenotech Laboratories standalone net profit declines 10.42% in the June 2024 quarter

Net profit of Zenotech Laboratories declined 10.42% to Rs 1.29 crore in the quarter ended June 2024 as against Rs 1.44 crore during the previous quarter ended June 2023. Sales rose 7.89% to Rs 8.89 crore in the quarter ended June 2024 as against Rs 8.24 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales8.898.24 8 OPM %38.7044.42 - PBDT3.783.86 -2 PBT2.052.06 0 NP1.291.44 -10 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Zenotech Laboratories schedules board meeting

Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Zenotech Laboratories standalone net profit declines 61.77% in the December 2022 quarter

1 year agoBusiness Standard

Stocks to Watch: Adani Enterprises, Bajaj Finance, Maruti Suzuki, Tata Motors

1 year agoLivemint

Zenotech Laboratories standalone net profit rises 191.58% in the September 2022 quarter

1 year agoBusiness Standard

Zenotech Laboratories standalone net profit rises 7.71% in the June 2022 quarter

2 years agoBusiness Standard

Zenotech Laboratories standalone net profit rises 5057.14% in the December 2021 quarter

2 years agoBusiness Standard

Zenotech Laboratories reports standalone net profit of Rs 0.95 crore in the September 2021 quarter

2 years agoBusiness Standard